SCHEMBL5164170

SCHEMBL5164170

CC(C)(O)c1cc(OCc2ccccc2)cc(C(C)(C)O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ CYP1A2 P05177 2/20 0.50
▸ LMNA P02545 1/20 0.50
▸ PTGS1 P23219 1/20 0.50
▸ SLC6A2 P23975 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ PTGS2 P35354 1/20 0.50
▸ SLC6A3 Q01959 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ HDAC6 Q9UBN7 1/20 0.50
▸ CYP1A1 P04798 1/20 0.49
▸ CYP19A1 P11511 1/20 0.49
▸ MAOB P27338 8/20 0.49
▸ ALOX5 P09917 1/20 0.47
▸ CYP4F2 P78329 1/20 0.46
▸ CYP4A11 Q02928 1/20 0.46
▸ NR4A2 P43354 3/20 0.45
▸ PDK1 Q15118 1/20 0.45
▸ PDK2 Q15119 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18802918 0.91 APP (0.46) MEN1KMT2AMAOBNR4A2NR4A1
SCHEMBL9434943 0.87 MAOB (0.58) MAOBALOX5CYP4F2CYP4A11NR4A2
SCHEMBL24533738 0.85 MAOB (0.38) MEN1KMT2AMAOBCYP4F2CYP4A11
SCHEMBL18811515 0.85 RXRA (0.47) MEN1KMT2AMAOBNR4A2NR4A1
SCHEMBL4602365 0.84 LMNA (0.61) MEN1KMT2ACYP1A2LMNAPTGS1
SCHEMBL9631198 0.83 MEN1 (0.53) MEN1KMT2ACYP1A2LMNAPTGS1
SCHEMBL5164975 0.83 MEN1 (0.49) MEN1KMT2ACYP1A2LMNAPTGS1
SCHEMBL5166880 0.83 MEN1 (0.51) MEN1KMT2ACYP1A2LMNAPTGS1
SCHEMBL20098899 0.82 MAOB (0.56) MEN1KMT2ACYP1A2LMNAPTGS1
SCHEMBL5165114 0.82 MEN1 (0.47) MEN1KMT2ACYP1A2LMNAPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1319646-B1 PROCESS FOR PREPARATION OF 3,5-BISALKYLPHENOLS KOWA CO (JP) 2007-04-18 — — EP disclosed
US-6806395-B2 FOR PRODUCING 3,5- DIISOPROPYLPHENOL OR A SIMILAR COMPOUND, WHICH SERVES AS AN INTERMEDIATE FOR PRODUCING ANTI-INFLAMMATORY AGENTS, PESTICIDES, ETC. KOWA CO., LTD. (JP) 2004-10-19 — — US disclosed
US-20040044255-A1 Process for preparation of 3,5-bisalkylphenols KOWA CO., LTD. (JP) 2004-03-04 — — US disclosed
EP-1319646-A1 PROCESS FOR PREPARATION OF 3,5-BISALKYLPHENOLS Kowa Co., Ltd. (JP) 2003-06-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044255-A1 Process for preparation of 3,5-bisalkylphenols ACSL3, HACL2, ARL1 MEN1 2978/4885KMT2A 2277/4885CYP1A2 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback